Suvorexant + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Delirium

Conditions

Delirium

Trial Timeline

Oct 22, 2020 → Dec 23, 2022

NCT ID

NCT04571944

About Suvorexant + Placebo

Suvorexant + Placebo is a phase 3 stage product being developed by Merck for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT04571944. Target conditions include Delirium.

What happened to similar drugs?

5 of 12 similar drugs in Delirium were approved

Approved (5) Terminated (3) Active (5)

✅Rivastigmine + PlaceboNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ParecoxibPfizerApproved

✅Cyclopofol + PropofolHaisco Pharmaceutical GroupApproved

✅Dexmedetomidine Hydrochloride GroupBrain BiotechApproved

🔄Rivastigmine prevention of deliriumNovartisPhase 3

🔄Rivastigmine transdermal patch + placebo patchNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06655883	Phase 3	Recruiting	Oct 9, 2025	Jun 24, 2027	Insomnia
NCT05823844	Approved	Recruiting	May 1, 2023	May 1, 2025	Postoperative Insomnia
NCT04571944	Phase 3	Completed	Oct 22, 2020	Dec 23, 2022	Delirium
NCT03110315	Approved	Completed	Mar 28, 2017	Mar 21, 2022	Multiple Sclerosis
NCT02750306	Phase 3	Completed	May 23, 2016	Sep 30, 2018	Sleep Initiation and Maintenance Disorders
NCT02729714	Approved	Completed	Apr 1, 2016	Apr 1, 2022	Insomnia
NCT02491788	Approved	Completed	Feb 1, 2016	Aug 1, 2019	Sleep Disorder, Shift-Work
NCT02527564	Approved	Completed	Sep 1, 2015	Mar 1, 2021	Insomnia
NCT01293006	Phase 1	Completed	Mar 25, 2011	Feb 22, 2012	Insomnia

Competing Products

17 competing products in Delirium

See all competitors

Product	Company	Stage	Hype Score
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	42
Suvorexant 20 mg + Placebo	Merck	Phase 2	35
Rivastigmine + Placebo	Novartis	Approved	35
Rivastigmine prevention of delirium	Novartis	Phase 3	40
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	40
Rivastigmine Patch	Novartis	Approved	43
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Parecoxib	Pfizer	Approved	39
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Pregabalin	Pfizer	Phase 3	40
Dexmedetomidine + Midazolam	Pfizer	Phase 3	47
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	26
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	38
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	39
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	37
Dexmedetomidine Hydrochloride Group	Brain Biotech	Approved	40
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	17